Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-03-06
2008-12-02
Stucker, Jeffrey (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600
Reexamination Certificate
active
07459440
ABSTRACT:
The present invention relates to a novel lacrimal gland protein (designated lacritin) and the nucleic acid sequences encoding that protein. Lacritin has activity as a growth factor on both human corneal epithelial cells and on the lacrimal acinar cells that produce it. Accordingly, one embodiment of the present invention is directed to the use of lacritin to treat Dry Eye and other disorders requiring the wetting of the eye.
REFERENCES:
patent: 2002/0101604 (2002-08-01), Edwards et al.
patent: 2002/0164669 (2002-11-01), Rueben et al.
patent: WO 98/27205 (1998-06-01), None
patent: WO 98/35229 (1998-08-01), None
Lumsden, A.J., Dickinson, D.P., and Laurie, G.W., (1998). “Paired oligonucleotide screening for ‘BM 180’ in a human lacrimal gland cDNA library: Clome HL-2”., Am. Society for Cell Biology Annual Meeting.
Sanghi, S., and Laurie, G.W.,, (1999). “cDNA Cloning and Expression of ‘lacritin’, a novel secreted glycoprotein of the lacrimal gland”., Am. Society for Cell Biology Annual Meeting.
Sanghi, S., Kumar, R. Walton, S., and Laurie, G.W., (2000)“Quantitation of rat lacrimal secretion: a novel sandwich ELISA with high sensitivity”., Exp. Eye Res., p. 651-658.
Rudinger, J., “Characteristics of the amino acids as components of a peptide hormone sequence”, Peptide Hormones, University Park Press (Baltimore), (Jun. 14, 1976).
Bork, Peer; “Powers and Pitfalls in Sequence Analysis” The 70% Hurdle, Genome Research, 2000, 10: 398-400, Cold Spring Harbor Laboratory Press.
Skolnick, et. al., “From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era”, TIBTECH, Jan. 2000, vol. 18: 34-39.
Doerks, et. al., “Protein Annotation: Detective Work for Function Prediction”, Trends in Genetics, Jun. 1998, vol. 14, No. 6: 248-250.
Smith, et. al., “The Challenges of Genome Sequence Annotation or ‘The Devil is in the Details’”, Nature Biotechnology, Nov. 1997, vol. 15: 1222-1223.
Boraschi, et. al., “Interleukin-1 and Interleukin-1 Fragments as Vaccine Adjuvants”, 1999, Methods, 19:108-113.
Prabhakaran, et. al., “Sequencing and Model Structure of a Naja naja atra Protein Fragment”, Journal of Peptide Research, 2000, 56: 12-23.
Fritz, Gerhard, “Molecules in focus—Human APE/Ref-1 Protein”, Int. Journal of Biochemistry, 2000, 32: 925-929.
Ma, et. al., “Heparanase Deglycanation of Syndecan-1 is Required for Binding of the Epithelial-Restricted Prosecretory Mitogen Lacritin”, Journal of Cell Biology, Sep. 25, 2006, vol. 174, No. 7, 1097-1106.
Wang, et. al., “Restricted Epithelial Proliferation by Lacritin via PKCα-dependent NFAT and mTOR Pathways”, Journal of Cell Biology, Aug. 28, 2006, vol. 174, No. 5, 689-700.
Laurie Gordon W.
Lumsden Angela J.
Rajesh Kumar
Sanghi Sandhya
Gucker Stephen
Sparks Rodney L.
Stucker Jeffrey
University of Virginia Patent Foundation
LandOfFree
Ocular tear growth factor-like protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ocular tear growth factor-like protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ocular tear growth factor-like protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4032650